A Randomized, Double-Blinded Study to Evaluate the Safety and Effect on Sustained Virological Response of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus Copegus, Compared With the Currently Approved Combination of PEGASYS Plus Copegus, in Treatment-naive Patients With Chronic hepatitis C
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Balapiravir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms POLI-1
- Sponsors Roche
- 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2009 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Dec 2008 Status changed from active, no longer recruiting to discontinued according to Roche.